Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 2Multiple Myeloma 1Lung Neoplasms 1Leukemia, Plasma Cell 1Ganglioneuroblastoma 1Adenoma, Islet Cell 1

Interventions

Carboplatin 29pembrolizumab 25Pemetrexed 25Specimen Handling 22Cisplatin 20Magnetic Resonance Spectroscopy 18Paclitaxel 15Gemcitabine 13Docetaxel 12durvalumab 9Nivolumab 8osimertinib 7Taxes 7Immunoglobulin G 7Disulfides 7130-nm albumin-bound paclitaxel 7atezolizumab 6Etoposide 6Platinum 5Cetuximab 51,2-diaminocyclohexaneplatinum II citrate 5X-Rays 4Ramucirumab 4Radiotherapy 4Radiation 4Observation 4Interviews as Topic 4Biopsy 4Albumin-Bound Paclitaxel 4patritumab deruxtecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Colony-Stimulating Factors × 30 days × Clear all
NCT07169617 2026-06-03

Testing the SurVaxM Vaccine for Lung Cancer Prevention

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
80 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡